Abstract: A double-deck rail vehicle and a vehicle body thereof are provided. An underframe (11) of the vehicle body comprises a lower-layer underframe (111), end underframes (112, 115), sealing plates (114, 116), and side underframes (118, 119); wherein the lower-layer underframe is provided with an underframe middle beam (1111); the end underframe is fixedly connected to the underframe middle beam by means of reinforcement middle beams (113, 117); the sealing plate is fixedly connected between the end underframe and the lower-layer underframe; and the side underframe comprises side beams (1181, 1191) of the side underframe that are integrated, and the side underframe is fixedly connected to the end underframe by means of the side beams of the side underframe. The vehicle body supplements the reinforcement middle beams capable of increasing the connection strength between the end underframe and the lower-layer underframe, and uses the integrated side beams of the side underframe.

Abstract: A compensation circuit, chip, method and device, a storage medium, and an electronic device are disclosed. The compensation circuit may include an analog module (102) including an input node (1022) and an output node (1024), wherein the input node (1022) is configured to receive an input signal and the output node (1024) is configured to output an output signal; and a linearity compensation module (104) including a plurality of transconductance units (1042), where the plurality of transconductance units (1042) are configured to acquire a first configuration signal and configure a combination of the plurality of transconductance units (1042) based on the first configuration signal to provide a compensation signal to the output node (1024), and the first configuration signal is configured to indicate a signal at any position in the analog module (102).

Abstract: The present invention relates to a WEE1 inhibitor, and the preparation and use thereof. The WEE1 inhibitor of the present invention is a compound of Formula I or a compound of Formula II, or a pharmaceutically acceptable salt, solvate, polymorph or tautomer thereof. The present invention also provides use of the WEE1 inhibitor in the manufacture of a medicament for the treatment of a disease associated with WEE1 activity. The WEE1 inhibitor provided by the present invention can effectively treat the disease associated with WEE1 activity.

Abstract: The present invention relates to a sulfoximine compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.

Abstract: An isotope nuclear magnetic method for analyzing ineffective water absorption of rock pores includes steps of: saturating core pores of a core sample with a wetting phase fluid of water H2O, and obtaining a core T2 spectrum after being saturated with the water; re-saturating the core pores with a wetting phase fluid of heavy water D2O, and obtaining a rock baseline T2 spectrum; injecting fluorinated oil into the core sample saturated with the heavy water; injecting the water H2O, simulating a water injection process, and injecting the fluorinated oil, so as to analyze a content of immobile water and obtain a residual T2 spectrum, wherein a range formed by a difference between the residual T2 spectrum and the rock baseline T2 spectrum is an ineffective water absorption portion of the rock pores, and an ineffective water absorption amount is obtained.

Abstract: An isotope nuclear magnetic method for analyzing ineffective water absorption of rock pores includes steps of: saturating core pores of a core sample with a wetting phase fluid of water H2O, and obtaining a core T2 spectrum after being saturated with the water; re-saturating the core pores with a wetting phase fluid of heavy water D2O, and obtaining a rock baseline T2 spectrum; injecting fluorinated oil into the core sample saturated with the heavy water; injecting the water H2O, simulating a water injection process, and injecting the fluorinated oil, so as to analyze a content of immobile water and obtain a residual T2 spectrum, wherein a range formed by a difference between the residual T2 spectrum and the rock baseline T2 spectrum is an ineffective water absorption portion of the rock pores, and an ineffective water absorption amount is obtained.

Abstract: The present application present application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.

Abstract: The present application relates to a preparation method of intermediate compounds with formula II and formula III of a compound (N-{3-[3-(9H-purin-6-yl) pyridin-2-ylamino]-4-chloro-2-fluorophenyl}-3-fluoropropane-1-sulfonamide) for regulating kinase activity.

Abstract: The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors. The compound of the present invention can irreversibly prevent EGFR phosphorylation, and effectively depress signal transduction of cancer cells, and accordingly has higher anti-tumor activity in vitro and in vivo.

Abstract: The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.

Abstract: The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors.

Abstract: A redirector, a relay, a system for configuring route information, and a method for updating route information are disclosed herein. The redirector includes: a route storing module and a route indicating module. The redirector further includes: a monitoring module which is coupled to communicate with the route storing module and configured to monitor change of the route configuration information; and a notifying module which is coupled to communicate with the monitoring module and configured to send a notification to the intermediate node managed by the redirector, where the notification indicates that the route information corresponding to the changed route configuration information is invalid. Through the foregoing solution, after the route configuration information changes, a notification may be sent in time to indicate that the previously subscribed route indication information is invalid, thus better ensuring correct forwarding of the service request message and improving the QoS.

Abstract: The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.

Abstract: The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula I, pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metabolic disorders and complications thereof, as well as methods for the treatment of the metabolic disorders and complications thereof.

Abstract: A method for compressing a table based on finite automata (FA) includes analyzing transferring characteristics of all states in an original two-dimensional structure table and combining continual states with unified transferring characteristics in the original two-dimensional structure table. A method for matching a table based on FA, a device for compressing a table, and a device for matching a table are also provided.

Abstract: A method, system, and apparatus for diagnosing a route in a network based on a Diameter protocol are provided. The method includes the following steps. A source Diameter node generates a diagnosis message and sends it. An intermediate Diameter node adds diagnosis information thereof to the diagnosis message after receiving it and forwards it until the diagnosis message is forwarded to a Diameter server capable of processing the diagnosis message or a Diameter node incapable of forwarding the diagnosis message. The Diameter server or the Diameter node generates a response message and sends it carrying diagnosis information thereof, information in the diagnosis message, and a response type. The intermediate Diameter node adds the diagnosis information thereof to the response message after receiving it, and forwards it until the response message is forwarded to the source Diameter node. The source Diameter node parses the response message to obtain route related information.

Abstract: A method for compressing a table based on finite automata (FA) includes analyzing transferring characteristics of all states in an original two-dimensional structure table and combining continual states with unified transferring characteristics in the original two-dimensional structure table. A method for matching a table based on FA, a device for compressing a table, and a device for matching a table are also provided.

Abstract: A method, system, and apparatus for diagnosing a route in a network based on a Diameter protocol are provided. The method includes the following steps. A source Diameter node generates a diagnosis message and sends it. An intermediate Diameter node adds diagnosis information thereof to the diagnosis message after receiving it and forwards it until the diagnosis message is forwarded to a Diameter server capable of processing the diagnosis message or a Diameter node incapable of forwarding the diagnosis message. The Diameter server or the Diameter node generates a response message and sends it carrying diagnosis information thereof, information in the diagnosis message, and a response type. The intermediate Diameter node adds the diagnosis information thereof to the response message after receiving it, and forwards it until the response message is forwarded to the source Diameter node. The source Diameter node parses the response message to obtain route related information.

Abstract: A redirector, a relay, a system for configuring route information, and a method for updating route information are disclosed herein. The redirector includes: a route storing module and a route indicating module. The redirector further includes: a monitoring module which is coupled to communicate with the route storing module and configured to monitor change of the route configuration information; and a notifying module which is coupled to communicate with the monitoring module and configured to send a notification to the intermediate node managed by the redirector, where the notification indicates that the route information corresponding to the changed route configuration information is invalid. Through the foregoing solution, after the route configuration information changes, a notification may be sent in time to indicate that the previously subscribed route indication information is invalid, thus better ensuring correct forwarding of the service request message and improving the QoS.